Cencora (COR) Financials

Cencora (NYSE: COR) shows strong revenue scale and solid quarterly profitability, but the balance sheet and cash flow trends are worth a careful look. Over the last several years, the company has continued to grow sales, but margins remain thin for a business of this size, and leverage has increased meaningfully in the most recent quarter.

• Revenue continues to grow year over year. Q2 2026 revenue rose to $78.4 billion from $75.5 billion in Q2 2025, while Q1 2026 revenue was also above the prior-year period.
• Profitability improved sharply in Q2 2026. Net income attributable to common shareholders reached $1.64 billion, up from $559.6 million in Q1 2026 and well above the $717.9 million reported in Q2 2025.
• Operating cash flow rebounded strongly in Q2 2026. Cash from operations was $1.34 billion, compared with negative operating cash flow in Q1 2026 and $3.35 billion in Q2 2025.
• The company remains a consistent cash generator over time. Despite quarter-to-quarter volatility, Cencora has generally produced positive operating cash flow across the multi-year period shown.
• Gross profit dollars are trending higher. Q2 2026 gross profit was $3.59 billion, up from $3.07 billion in Q1 2026 and $3.06 billion in Q2 2025.
• EPS remains healthy. Diluted EPS was $8.40 in Q2 2026, a strong result even though the quarter’s margin profile is still relatively tight.
• Margins are still thin for a company this large. Q2 2026 gross margin was only about 4.6% ($3.59 billion gross profit on $78.36 billion revenue), which is typical for distribution, but leaves limited room for error.
• Inventory and receivables remain very large. These working-capital items are central to the business model, but they also make cash flow sensitive to operating timing and seasonal changes.
• Large goodwill and intangible asset balances remain on the books. As of Q2 2026, goodwill was $16.45 billion and intangibles were $6.05 billion, so acquisition-related assets are a meaningful part of the balance sheet.
• Debt jumped materially in Q2 2026. Long-term debt rose to $12.18 billion from $7.58 billion in Q1 2026, and total debt was far higher than earlier periods shown.
• Liquidity tightened versus last year. Cash and equivalents were $2.18 billion in Q2 2026, down from $3.22 billion in Q1 2025 and below the level seen in several prior periods.
• Equity remains very low relative to liabilities. Total equity and noncontrolling interests were just $3.58 billion versus $78.07 billion in total liabilities, which reflects a highly leveraged capital structure.
• Acquisition spending has been heavy. Q2 2026 included $4.72 billion of acquisition-related cash outflows, following a series of acquisition-driven investing periods over the last several quarters.
• Non-operating items and special charges continue to affect earnings. Restructuring charges, special charges, and other income/expense items have been recurring features of the income statement, which can make earnings quality less clean.
• Quarterly cash flow can swing sharply. Q1 2026 operating cash flow was negative $2.31 billion, showing that working-capital timing can materially distort short-term results.

Bottom line: Cencora is still a fundamentally large and profitable healthcare distributor with strong top-line growth and recurring cash generation, but investors should watch leverage, acquisition spending, and working-capital volatility closely. The business looks resilient, yet the balance sheet is carrying more debt than in the recent past, and that is the main risk to monitor.